药物涂层球囊(drug-coated balloon, DCB)作为经皮冠状动脉介入治疗(percutaneous coronary intervention, PCI)领域的新器械,在不留置永久性植入物的情况下有效抑制狭窄,特别在冠状动脉原位小血管病变(small vessel disease, SVD)和支...药物涂层球囊(drug-coated balloon, DCB)作为经皮冠状动脉介入治疗(percutaneous coronary intervention, PCI)领域的新器械,在不留置永久性植入物的情况下有效抑制狭窄,特别在冠状动脉原位小血管病变(small vessel disease, SVD)和支架内再狭窄(in-stent restenosis, ISR)病变中显示出较优的疗效。随着影像学技术的发展,光学相干断层成像(optical coherence tomography, OCT)、血管内超声(intravascular ultrasound, IVUS)引导下的DCB治疗能够进一步提高其临床效果,降低主要不良心血管事件(major adverse cardiac events, MACE)的发生率,使其在冠脉病变治疗中的应用范围不断扩大。本文就目前DCB应用于冠脉原位病变做一综述。Drug-coated balloon (DCB), as a new device in the field of percutaneous coronary intervention (PCI), effectively inhibits stenosis without indwelling permanent implants. In particular, it has shown better efficacy in coronary primary small vessel disease (SVD) and in-stent restenosis (ISR) lesions. With the development of imaging technology, DCB treatment guided by optical coherence tomography (OCT) and intravascular ultrasound (IVUS) can further improve its clinical efficacy. It can reduce the incidence of major adverse cardiac events (MACE) and expand its application in the treatment of coronary artery disease. This article reviews the current application of DCB in de novo coronary lesions.展开更多
文摘药物涂层球囊(drug-coated balloon, DCB)作为经皮冠状动脉介入治疗(percutaneous coronary intervention, PCI)领域的新器械,在不留置永久性植入物的情况下有效抑制狭窄,特别在冠状动脉原位小血管病变(small vessel disease, SVD)和支架内再狭窄(in-stent restenosis, ISR)病变中显示出较优的疗效。随着影像学技术的发展,光学相干断层成像(optical coherence tomography, OCT)、血管内超声(intravascular ultrasound, IVUS)引导下的DCB治疗能够进一步提高其临床效果,降低主要不良心血管事件(major adverse cardiac events, MACE)的发生率,使其在冠脉病变治疗中的应用范围不断扩大。本文就目前DCB应用于冠脉原位病变做一综述。Drug-coated balloon (DCB), as a new device in the field of percutaneous coronary intervention (PCI), effectively inhibits stenosis without indwelling permanent implants. In particular, it has shown better efficacy in coronary primary small vessel disease (SVD) and in-stent restenosis (ISR) lesions. With the development of imaging technology, DCB treatment guided by optical coherence tomography (OCT) and intravascular ultrasound (IVUS) can further improve its clinical efficacy. It can reduce the incidence of major adverse cardiac events (MACE) and expand its application in the treatment of coronary artery disease. This article reviews the current application of DCB in de novo coronary lesions.
